Close Menu

NEW YORK (360Dx) – T2 Biosystems announced today that it has received a grant worth up to $2 million by CARB-X in order to accelerate the development of new tests to identify bacterial pathogens and resistance markers. The new tests will increase the T2Dx instrument product line by detecting 20 additional bacterial species and resistance targets in whole blood samples, with a focus on blood-borne pathogens on the US Centers for Disease Control and Prevention's antibiotic resistance threat list.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.